ETFs positioned on GSK plc

Name YTD change Weight AuM
+10.20%-.--% 24,432 M€
+12.84%-.--% 750 M€
-.--%-.--% 22 M€
+10.01%-.--% 44 M€
+5.27%-.--% 49 M€
+0.76%-.--% 51 M€
+9.41%-.--% 66 M€
+7.74%-.--% 75 M€
+7.97%-.--% 6,576 M€
+9.43%-.--% 274 M€
+10.13%-.--% 122 M€
+7.13%-.--% 1,193 M€
+12.73%-.--% 1,674 M€
+7.51%9.81% 28 M€
+4.77%8.02% 9 M€
+7.36%7.14% 987 M€
-.--%7.14% 987 M€
+8.15%6.59% 12 M€
-2.10%5.94% 1,024 M€
+6.56%5.9% 38 M€
+4.58%5.9% 90 M€
+5.13%5.86% 56 M€
-2.06%5.75% 12 M€
-3.97%5.75% 820 M€
+2.87%5.14% 58 M€
+5.67%5.09% 11 M€
-1.49%5.09% 667 M€
+6.42%5.02% 19 M€
+1.91%4.94% 9 M€
+3.08%4.92% 1,018 M€
0.00%4.18% 8 M€
+48.10%4.1% 215 M€
+14.76%4.03% 1,807 M€
+9.27%3.8% 2,529 M€
+7.20%3.62% 50 M€
+7.05%3.57% 106 M€
+5.61%3.57% 19 M€
+7.28%3.57% 147 M€
+10.63%3.57% 1,166 M€
+8.36%3.48% 935 M€
+7.02%3.36% 1,190 M€
-.--%3.36% 1,190 M€
+14.09%3.33% 114 M€
+10.06%3.33% 265 M€
+10.29%3.31% 1,211 M€
Logo GSK plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
66,841
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!